Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




CE-Marked IVD Sequencing Platform Launches Across Ten EU Countries

By LabMedica International staff writers
Posted on 30 Oct 2026

Clinical laboratories using sequencing in regulated diagnostic workflows need systems that support clearly defined processes and documentation. More...

In Europe, meeting applicable EU IVDR requirements also means maintaining consistency, traceability, and reliability across decentralized diagnostic settings. To support these needs, a newly launched platform brings CE-marked IVD sequencing capabilities to clinical laboratories in ten EU countries through integrated instrumentation, reagents, and software.

Element Biosciences, Inc. (San Diego, CA, USA) has commercially launched AVITI Dx, its first CE-marked in vitro diagnostic (IVD) sequencing platform under the European Union’s In Vitro Diagnostic Regulation (EU IVDR). The platform combines Element’s AVITI sequencing system with dedicated reagents and software designed to meet applicable IVDR requirements. The commercial launch spans the Netherlands, Germany, France, Italy, Spain, Austria, the Czech Republic, Latvia, Romania, and Poland.

Developed and manufactured under Element’s ISO 13485-certified quality management system, AVITI Dx is a Class A IVD sequencing system designed to support regulated clinical laboratory workflows. It uses the same chemistry that powers Element’s other solutions, with a dual-boot configuration that allows a single instrument to switch between IVD and research use only (RUO) modes. Dedicated reagents and software maintain separation between diagnostic workflows and research applications.

To support use across these markets, the AVITI Dx software interface offers multiple languages, allowing laboratories to operate in their regional language. Together with IVDR-compliant reagents and software, this configuration is intended to provide flexibility and scalability for decentralized diagnostic settings. Element plans to extend access through a phased expansion into additional European markets, followed by select Asia-Pacific markets.

 “Launching AVITI Dx across ten EU markets reflects years of investment in the quality systems, manufacturing capabilities, and global supply chain needed to support regulated clinical markets. Our ISO 13485-certified quality management system and established manufacturing controls provide the foundation for delivering an integrated sequencing platform with the consistency, traceability, and reliability that clinical laboratories expect,” said Jeff Labbadia, Chief Supply Chain Officer at Element Biosciences.

Related Links
Element Biosciences


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Neurofilament Light Chain Assay
Lumipulse G NfL Blood
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New evidence now questions whether a single stool-test cutoff should be applied uniformly across all age groups.(Photo courtesy of Paul Maguire - Adobe Stock)

Study Questions Uniform Stool-Test Cutoff Across Age Groups

Colorectal cancer remains a major clinical challenge, ranking as the fourth most common cancer and the second-leading cause of cancer death in the U.K. Early-onset colorectal cancer, defined as diagnosis... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.